Skip to main content
Equibles

UBS Group AG

Position in LLY — ELI LILLY & Co

CIK 1610520 ZURICH, V8
Back to LLY Full portfolio

Position in LLY

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$3,719,152,536
-$110,921,360 QoQ
Shares Held
4,043,568
+13.5% QoQ
Ownership
0.429%
of shares outstanding
% of Portfolio
0.89%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 25.16888549914333.ToString("F0")% Shared 0.ToString("F0")% None 74.83111450085667.ToString("F0")%

Common Shares in LLY Over Time

Shares Held

Position Value (USD)

Derivatives in LLY

reported options exposure · as of Mar 31, 2026
CallValue
$143,749,013
CallShares
156,288
PutValue
$364,320,897
PutShares
396,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

UBS Group AG holds $15,459,459,109 across 21 Drug Manufacturers - General names. LLY ranks #1 (24.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
This page 		4,043,568 $3,719,152,536
2 ABBV
AbbVie Inc.
 14,051,196 $3,055,994,614
3 JNJ
Johnson & Johnson
 10,209,327 $2,495,567,886
4 MRK
Merck & Co., Inc.
 13,933,630 $1,676,076,347
5 AZN
Astrazeneca PLC
 5,981,411 $1,179,653,872
6 AMGN
Amgen Inc
 3,148,040 $1,107,637,870
7 GILD
Gilead Sciences, Inc.
 3,930,216 $547,754,202
8 PFE
Pfizer Inc
 17,609,150 $494,464,929

All Filings in LLY

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $143,749,013 156,288
2026-03-31 $364,320,897 396,100
2026-03-31 $3,719,152,536 4,043,568
2025-12-31 $3,830,073,896 3,563,920
2025-12-31 $256,994,700 239,136
2025-12-31 $357,636,342 332,784
2025-09-30 $3,029,296,935 3,970,245
2025-09-30 $300,922,622 394,394
2025-09-30 $217,851,760 285,520
2025-06-30 $162,850,832 208,909
2025-06-30 $311,601,526 399,730
2025-06-30 $3,055,295,333 3,919,407
2025-03-31 $136,608,817 165,404
2025-03-31 $375,541,277 454,700
2025-03-31 $3,170,546,249 3,838,852
2024-12-31 $190,143,600 246,300
2024-12-31 $130,000,168 168,394
2024-12-31 $2,625,679,308 3,401,139
2024-09-30 $164,956,712 186,194
2024-09-30 $247,443,042 279,300
2024-09-30 $3,185,768,471 3,595,919
2024-06-30 $129,065,540 142,554
2024-06-30 $2,682,478,868 2,962,821
2024-06-30 $167,042,610 184,500
2024-03-31 $2,092,109,477 2,689,225
2024-03-31 $129,841,524 166,900
2024-03-31 $164,305,152 211,200
2023-12-31 $126,488,976 216,992
2023-12-31 $1,482,936,233 2,543,979
2023-12-31 $154,696,475 265,382
2023-09-30 $1,194,051,265 2,223,021
2023-09-30 $42,057,279 78,300
2023-09-30 $58,154,527 108,269
2023-06-30 $19,462,670 41,500
2023-06-30 $1,144,523,644 2,440,453
2023-06-30 $26,591,166 56,700
2023-03-31 $12,740,882 37,100
2023-03-31 $800,483,511 2,330,917
2023-03-31 $17,926,524 52,200
2022-12-31 $16,353,048 44,700
2022-12-31 $24,989,432 68,307
2022-12-31 $697,983,205 1,907,892
2022-09-30 $10,023,850 31,000
2022-09-30 $1,616,750 5,000
2022-09-30 $340,187,799 1,052,073
2022-06-30 $8,429,980 26,000
2022-06-30 $384,824,044 1,186,886
2022-03-31 $9,851,128 34,400
2022-03-31 $8,018,360 28,000
2022-03-31 $349,663,780 1,221,021

Report a Problem

Category
Description
Email (optional, for follow-up)